Sugi Predict

Sugi Predict / Compounds / SCHEMBL6098429

SCHEMBL6098429

SCHEMBL6098429

C[C@@H](O)c1ccc(Cl)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 4/20 0.46
▸ KCNH2 Q12809 2/20 0.45
▸ HTT P42858 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ MDM2 Q00987 1/20 0.41
▸ CXCR3 P49682 1/20 0.38
▸ DPP4 P27487 1/20 0.37
▸ DPP7 Q9UHL4 1/20 0.37
▸ PSEN1 P49768 1/20 0.37
▸ PSEN2 P49810 1/20 0.37
▸ APH1B Q8WW43 1/20 0.37
▸ NCSTN Q92542 1/20 0.37
▸ APH1A Q96BI3 1/20 0.37
▸ PSENEN Q9NZ42 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2295810 1.00 PDE2A (0.46) PDE2AKCNH2HTTLMNATP53
SCHEMBL29924355 1.00 PDE2A (0.46) PDE2AKCNH2HTTLMNATP53
SCHEMBL30399466 1.00 PDE2A (0.46) PDE2AKCNH2HTTLMNATP53
SCHEMBL17215353 1.00 PDE2A (0.46) PDE2AKCNH2HTTLMNATP53
SCHEMBL23489755 0.85 KCNH2 (0.46) PDE2AKCNH2HTTLMNATP53
SCHEMBL20238442 0.85 KCNH2 (0.46) PDE2AKCNH2HTTLMNATP53
SCHEMBL20238444 0.85 KCNH2 (0.46) PDE2AKCNH2HTTLMNATP53
SCHEMBL84107 0.83 LMNA (0.47) PDE2AKCNH2HTTLMNATP53
SCHEMBL1350237 0.83 KCNH2 (0.45) PDE2AKCNH2HTTLMNATP53
SCHEMBL22852398 0.83 KCNH2 (0.45) PDE2AKCNH2HTTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199620-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2024-06-20 — — US disclosed
CN-109789146-B Chemokine receptor modulators and uses thereof 拉普特医疗公司 2023-04-18 — — CN disclosed
EP-3490565-B1 AZETIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2022-06-08 — — EP disclosed
EP-3490565-B1 AZETIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2022-06-08 — — EP disclosed
US-20200239480-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2020-07-30 — — US disclosed
US-20200239480-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2020-07-30 — — US disclosed
US-10604526-B2 Chemokine receptor modulators and uses thereof RAPT THERAPEUTICS, INC. (US) 2020-03-31 — — US disclosed
US-10604526-B2 Chemokine receptor modulators and uses thereof RAPT THERAPEUTICS, INC. (US) 2020-03-31 — — US disclosed
EP-3490565-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF FLX Bio, Inc. (US) 2019-06-05 — — EP disclosed
US-20190152978-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2019-05-23 — — US disclosed
WO-2018049271-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF FLX BIO, INC. (US) 2018-03-15 — — WO disclosed
US-20180072743-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2018-03-15 — — US disclosed
US-20180072743-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2018-03-15 — — US disclosed
US-20180072743-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2018-03-15 — — US disclosed
US-20180072740-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2018-03-15 — — US disclosed
WO-2018022992-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF FLX BIO, INC. (US) 2018-02-01 — — WO disclosed
WO-2018022992-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF FLX BIO, INC. (US) 2018-02-01 — — WO disclosed
CN-1894213-A Substituted tetrahydrocarbazole and cyclopentanoindole derivatives MERCK & CO INC (CA) 2007-01-10 — — CN disclosed
US-7019022-B2 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives MERCK FROSST CANADA & CO. (CA) 2006-03-28 — — US disclosed
US-20050154044-A1 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives MERCK FROSST CANADA LTD. (CA) 2005-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152978-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF CCR4, CCR1, CCR3 PDE2A 767/4885KCNH2 4825/4885HTT 4810/4885
US-10604526-B2 Chemokine receptor modulators and uses thereof CCR4, CCR1, CCR3 PDE2A 767/4885KCNH2 4825/4885HTT 4810/4885
US-20200239480-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF CCR4, CCR1, CCR3 PDE2A 767/4885KCNH2 4825/4885HTT 4810/4885
US-20180072743-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF ACKR3, CCR5, CXCR3 PDE2A 797/4885KCNH2 4819/4885HTT 4765/4885
US-20180072740-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF CCR4, CCR1, CCR3 PDE2A 767/4885KCNH2 4825/4885HTT 4810/4885
US-20050154044-A1 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives PTGIR, PTGDR, PTGDR2 PDE2A 1080/4885KCNH2 3024/4885HTT 4118/4885
US-20240199620-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF CCR4, CCR1, CCR3 PDE2A 767/4885KCNH2 4825/4885HTT 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.